Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
      • T-Cell Adaptive Vaccine
      • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
      • Technical Support Position
  • Contact Us
  • Menu Menu
You are here: Home1 / Pipeline

We have a growing pipeline of vaccine candidates.

Lead programme: SARS-CoV-1/SARS-CoV-2 Coronavirus vaccine and Dengue Fever vaccine

Our next-generation T-Cell Adaptive Vaccine candidates have the potential to tackle major global diseases and can offer efficacy against a range of viral pathogens including Dengue, Coronavirus, Influenza, Zika, Yellow fever, as well as intracellular bacteria.

Development programmes

We also have programmes in development for a universal Influenza (flu) vaccine, a universal Filovirus vaccine (to target viruses including Ebola and Marburg), a Yellow Fever Booster vaccine, and a Chikungunya virus vaccine.

We are also working on vaccines for several intracellular bacterial infections, such as Francisella tularensis, currently categorized as a Tier 1 biothreat priority by the US government.

Partnered programmes

We have partnered with the IMCB of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease.

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top